These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32981939)

  • 1. Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-The-Losers Design.
    Karanevich A; Meier R; Graw S; McGlothlin A; Gajewski B
    Am Stat; 2019; 2019():. PubMed ID: 32981939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A web application for the design of multi-arm clinical trials.
    Grayling MJ; Wason JM
    BMC Cancer; 2020 Jan; 20(1):80. PubMed ID: 32005187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly Efficient Clinical Trials Simulator (HECT): Software application for planning and simulating platform adaptive trials.
    Thorlund K; Golchi S; Haggstrom J; Mills E
    Gates Open Res; 2019; 3():780. PubMed ID: 31259314
    [No Abstract]   [Full Text] [Related]  

  • 4. A multi-stage drop-the-losers design for multi-arm clinical trials.
    Wason J; Stallard N; Bowden J; Jennison C
    Stat Methods Med Res; 2017 Feb; 26(1):508-524. PubMed ID: 25228636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
    Lin J; Bunn V
    Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and analysis of drop-the-losers studies using binary endpoints in the rare disease setting.
    Jazić I; Liu X; Laird G
    J Biopharm Stat; 2021 Jul; 31(4):507-522. PubMed ID: 34053399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving adaptive seamless designs through Bayesian optimization.
    Richter J; Friede T; Rahnenführer J
    Biom J; 2022 Jun; 64(5):948-963. PubMed ID: 35212423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MSE FINDR: A Shiny R Application to Estimate Mean Square Error Using Treatment Means and Post Hoc Test Results.
    Garnica VC; Shah DA; Esker PD; Ojiambo PS
    Plant Dis; 2024 Jun; ():PDIS11232519SR. PubMed ID: 38319624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A two-stage drop-the-losers design for time-to-event outcome using a historical control arm.
    Abbas R; Wason J; Michiels S; Le Teuff G
    Pharm Stat; 2022 Jan; 21(1):268-288. PubMed ID: 34496117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROpwr: a Shiny R application to analyze patient-reported outcomes data and estimate power.
    Hu J; Mei X; Pepper S; Wang Y; Zhang B; Cernik C; Gajewski B
    J Biopharm Stat; 2024 Jun; ():1-12. PubMed ID: 38869267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive multiarm multistage clinical trials.
    Ghosh P; Liu L; Mehta C
    Stat Med; 2020 Apr; 39(8):1084-1102. PubMed ID: 32048313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal designs for phase II/III drug development programs including methods for discounting of phase II results.
    Erdmann S; Kirchner M; Götte H; Kieser M
    BMC Med Res Methodol; 2020 Oct; 20(1):253. PubMed ID: 33036572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
    Zhou H; Lee JJ; Yuan Y
    Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development.
    Broglio K; Cooner F; Wu Y; Xiao M; Xue XQ; Lowen M; Ikhapoh I; He P
    Ther Innov Regul Sci; 2024 Jun; ():. PubMed ID: 38861131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drop-the-losers design: normal case.
    Sampson AR; Sill MW
    Biom J; 2005 Jun; 47(3):257-68; discussion 269-81. PubMed ID: 16053251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized multi-stage designs controlling the false discovery or the family-wise error rate.
    Zehetmayer S; Bauer P; Posch M
    Stat Med; 2008 Sep; 27(21):4145-60. PubMed ID: 18444249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.